P1.020. Real-World Deviations From Standard Adjuvant Immunotherapy After Esophagectomy
Clicks: 4
ID: 325734
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.9
/100
4 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #60 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Adjuvant IO is recommended within 4–16 weeks post-esophagectomy, but delays and interruptions are common in practice. Trials like CheckMate 577 permitted treatment delays of up to 10 weeks. We evaluated how often patients deviate from standard timing and explored the clinical impact of delays, interruptions, or early discontinuation. Methods We retrospectively reviewed 45 patients who underwent esophagectomy and received neoadjuvant therapy who did not have a pathologic complete response (2022 - 2025). Patients were classified into three groups based on adjuvant IO receipt and delivery: no adjuvant immunotherapy (IO) (n=14), standard IO (initiated within 10 weeks and completed without interruption; n=26), and modified IO (any delay, interruption, or early discontinuation; n=5). We compared clinical characteristics, timing intervals, and outcomes across groups. Results Baseline demographics, comorbidities, performance status and post operative outcomes were similar across all groups. The average age was 67.9 years and most patients were male (84.4%), white (64.4%), and underwent Ivor Lewis esophagectomy (93.3%) for adenocarcinoma (90.9%). Of the 31 patients who initiated IO, 83.9% completed the standard course, while 16.1% had delays, interruptions, or early discontinuation due to toxicity/complications(60%), or disease progression(40%). Time from surgery to IO was significantly longer in the modified group (81 vs 41 days, p=0.001). Treatment delays occurred in 80% of modified IO patients; 40% had interruptions or early discontinuation. Mean hospital length of stay differed significantly across groups: 17 days in the no IO group, 7 days in the standard IO group, and 6 days in the modified IO group (p=0.004). All 30-day mortality occurred in the no IO group (6.8%), compared to 0% in the other groups (p=0.06). Conclusion In this small retrospective cohort, deviations from standard adjuvant IO occurred in a minority of patients and were primarily associated with post-operative complications, toxicity, or disease progression. These deviations were not linked to system-level delays. While limited by sample size, the findings suggest that clinical recovery and disease trajectory are key factors influencing standard IO adherence. Identifying patients at risk for modification preoperatively may help tailor perioperative care and support more consistent delivery of adjuvant therapy.
| Reference Key |
openalex_W7203927891
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Evelyn Alexander, Serena Persaud, Ahmed Elkamel, Mazin Abdalgadir, Shamele Battan-Wraith, Jonathan Rice, Praveen Sridhar, Stephanie Worrell |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.168
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.